207) ence determinants framework (January 1999 through August 2018). |
208) t clinical intervention studies conducted through August 2020. |
209) of evidence: A search has been performed through Google Scholar and two other disci |
210) Relevant publications were selected through Google Scholar, Web of Science, Pu |
211) Literature was searched through MEDLINE, EMBASE, Ovid Emcare, SPOR |
212) A search through MEDLINE, SCOPUS, WOS and CINHAL da |
213) Publications were identified through Medline, CINAHL, EMBASE, and PsycI |
214) uage, full-text resources were identified through Medline, PsycINFO, SPORTDiscus, We |
215) All articles available through PubMed and Scopus up until the sea |
216) ly screened and a related-articles search through PubMed was performed on all includ |
217) We searched through PubMed, Embase, Scopus, Cochrane L |
218) ethods: A systematic search was performed through PubMed, Web of Science and Scopus, |
219) actors to improve the stress distribution through abutment and implants composed of |
220) an enhancement on the stress distribution through abutment and implants towards to t |
221) Through analysis of human movement, contac |
222) Through analysis of human movement, contac |
223) le and cerebrovascular disease, confirmed through assessment of vascular neuropathol |
224) ge and cerebrovascular disease, confirmed through assessment of vascular neuropathol |
225) iotensin system (RAS) that generally acts through binding to two main classes of G p |
226) cts on the absorption of other oral drugs through binding to veverimer in the gastro |
227) d promote intracellular CuET accumulation through dual action without changing CuET |
228) promote the enrichment of CuET in tumors through dual action. |
229) f calcium and with decreasing conductance through gap junctions in PCs. |
230) ion as well as with conductance reduction through gap junctions, SPW-Rs are suppress |
231) Through genetic analysis, we confirmed tha |
232) of children with any condition diagnosed through genetic testing. |
233) agent for ischemic cardiomyopathy, likely through improving energy homeostasis, left |
234) tional and local efforts to close the gap through improving health insurance access, |
235) to MAPK activation in vitro and in vivo through induction of cell-cycle arrest and |
236) rsely, TFEB, in a steady-state condition, through induction of lysosomal biogenesis |
237) r lipophilic ions to effectively permeate through lipid membranes. |
238) ketoaldehydes formed from H2-isoprostanes through lipid peroxidation and crosslink p |
239) PRR) parties can impact population health through multiple mechanisms, including wel |
|